Pregled bibliografske jedinice broj: 1040083
Management of antiplatelet therapy resistance in cardiac surgery
Management of antiplatelet therapy resistance in cardiac surgery // The Journal of Thoracic and Cardiovascular Surgery, 147 (2014), 3; 855-862 doi:10.1016/j.jtcvs.2013.10.008 (međunarodna recenzija, članak, ostalo)
CROSBI ID: 1040083 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Management of antiplatelet therapy resistance in cardiac surgery
Autori
Gasparovic, Hrvoje ; Petricevic, Mate ; Biocina, Bojan
Izvornik
The Journal of Thoracic and Cardiovascular Surgery (0022-5223) 147
(2014), 3;
855-862
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, ostalo
Ključne riječi
antiplatelet therapy ; coronary artery surgery ; drug resistance
Sažetak
The role of coronary artery bypass grafting (CABG) in the management of complex coronary artery disease has been validated through an unparalleled level of scrutiny. Improvement in patient outcomes currently relies on continued refinements of the surgical technique and modulation of adjuvant pharmacotherapy. Postoperative antiplatelet therapy (APT) is paramount in maintaining the revascularization benefit. However, individual variability to APT results in unpredictable platelet inhibition. Currently available platelet function tests (PFTs) dichotomize patients into “responders” and “nonresponders” on the basis of arbitrarily defined cutoff points. It is not surprising that the incidence of APT resistance across the spectrum of PFTs is widely discrepant, underscoring the fact that single pathway descriptors of platelet aggregation fail to portray the complexity of the process. Thrombosis is the principal mode of failure of saphenous vein grafts (SVGs) in the early postoperative period.1 Reports on the increased incidence of SVG failure in patients experiencing antiplatelet agent resistance underscore the importance of recognizing this entity and intervening in a timely fashion. This review summarizes the various assay- dependent definitions of APT resistance, with their respective rates of occurrence. The clinical impact of on-therapy high residual platelet reactivity (hRPR) in the cardiac surgical arena is discussed. Finally, guidelines on individual tailoring of APT in patients found to retain high on-therapy platelet reactivity are suggested.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE